Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 1784.TWO and 80,000+ other tickers.
See exactly how 1784.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 1784.TWO and 80,000+ other tickers.
Established in 1989 and headquartered in Taipei City, Taiwan, BIONET Corp. is a global leader in umbilical cord blood preservation, serving clients across Taiwan and internationally. The company provides a comprehensive suite of stem cell banking services, encompassing the storage of general stem cells, mesenchymal stem cells, dental stem cells, adipose stem cells, and peripheral blood stem cells combined with immune cells. Beyond its core stem cell preservation, BIONET also conducts genetic testing services. Its product offerings further extend to anti-aging solutions leveraging stem cell…
No recent news available.